Antibiotic Development Question: Should A Phage Library Equal One Application?
FDA may have to take a personalized medicine approach when deciding how to classify a phage bank used to create the treatments.
You may also be interested in...
US FDA draft guidance on Limited Population Antibacterial Drug pathway says eligibility considerations for preventative products will center on size of population receiving drug, not incidence of infection.
US FDA Commissioner outlines licensing fee reimbursement arrangement intended to provide better financial incentives for development.
Emerging Company Profile: Where other microbiome-focused firms seek to add bacteria to the patient's gut, Israel's BiomX thinks it can treat IBD and other conditions with phage therapies that subtract harmful microbiota.